Superior efficacy of a cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in chinese patients with metastatic breast cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 3, 2009, Pages 165-174

  Guan, Zhong Zhen ^a   Li, Qing Li ^b   Feng, Fengyi ^c   Jiang, Zefei ^d   Shen, Zhenzhou ^e   Yu, Shiying ^f   Fen, Jifeng ^g   Huang, Jianjin ^h   Yao, Zhiwen ⁱ   Bhar, Paul ⁱ  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Tianjin Hospital   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d Beijing 307 Hospital   (China)

^e FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^f Tonghi Hospital   (China)

^g Jiansu Tumor Hospital   (China)

^h ZHEJIANG UNIVERSITY   (China)

ⁱ Abraxis BioScience   (United States)

Author keywords

Albumin bound paclitaxel; Chemotherapy; Metastatic breast cancer; Nab paclitaxel; Paclitaxel; Randomized trial

Indexed keywords

ALBUMIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; CREMOPHOR; NANOPARTICLE; PACLITAXEL; SOLVENT;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CHINESE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 70350108686     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01235.x     Document Type: Article

References (14)

1. Taxol (Paclitaxel) Injection: Package Insert 2003, Bristol-Myers Squibb, Princeton NJ
2. Weiss RB, Donehower RC, Wiernik PH. Hypersensitivity reactions from taxol. J Clin Oncol 1990, 8:1263-38.
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-8.
4. Lorenz W, Reimann HJ, Schmal A. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977, 7:63-7.
5. Desai N, Trieu V, Yao Z. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006, 12:1317-24.
6. Gradishar WJ, Tjulandin S, Davidson N. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-803.
7. Teng XY, Guan ZZ, Yao ZW. A tolerability study of A cremophor-free albumin bound nanoparticle paclitaxel intravenously administered in patients with advanced solid tumor. Ai Zheng 2004, 23:1431-36.
8. Ibrahim NK, Desai N, Legha S. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-44.
9. ABRAXANE Package Insert Version 12/January 7, 2005 2005, Abraxis BioScience, Los Angeles CA
10. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-16.
11. Kim YW, Park YK, Lee J, Ko SW, Yang MH. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 1998, 13:652-57.
12. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003, 14:3977-88.
13. Winer EP, Berry DA, Woolf S. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004, 22:2061-68.
14. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001, 19:125-41.